Bigalke H - Search Results

1

Secondary non-response due to development of neutralising antibodies to botulinum toxin A during treatment of children with cerebral palsy.

Herrmann J, Mall V, Bigalke H, Geth K, Korinthenberg R, Heinen F. Herrmann J, et al. Among authors: bigalke h. Neuropediatrics. 2000 Dec;31(6):333-4. doi: 10.1055/s-2000-12955. Neuropediatrics. 2000. PMID: 11508557 Clinical Trial. No abstract available.

2

Clinical impact of antibody formation to botulinum toxin A in children.

Herrmann J, Geth K, Mall V, Bigalke H, Schulte Mönting J, Linder M, Kirschner J, Berweck S, Korinthenberg R, Heinen F, Fietzek UM. Herrmann J, et al. Among authors: bigalke h. Ann Neurol. 2004 May;55(5):732-5. doi: 10.1002/ana.20098. Ann Neurol. 2004. PMID: 15122715

3

Secondary non-response due to antibody formation in a child after three injections of botulinum toxin B into the salivary glands.

Berweck S, Schroeder AS, Lee SH, Bigalke H, Heinen F. Berweck S, et al. Among authors: bigalke h. Dev Med Child Neurol. 2007 Jan;49(1):62-4. doi: 10.1017/s0012162207000151.x. Dev Med Child Neurol. 2007. PMID: 17209979 Free article.

4

[The pharmacology of botulinum toxin].

Bigalke H. Bigalke H. Med Monatsschr Pharm. 2002 Sep;25(9):305-8. Med Monatsschr Pharm. 2002. PMID: 12369431 Review. German. No abstract available.

5

Neutralizing antibodies and secondary therapy failure after treatment with botulinum toxin type A: much ado about nothing?

Lange O, Bigalke H, Dengler R, Wegner F, deGroot M, Wohlfarth K. Lange O, et al. Among authors: bigalke h. Clin Neuropharmacol. 2009 Jul-Aug;32(4):213-8. doi: 10.1097/WNF.0b013e3181914d0a. Clin Neuropharmacol. 2009. PMID: 19620852

6

Depletion of neutralising antibodies resensitises a secondary non-responder to botulinum A neurotoxin.

Naumann M, Toyka KV, Mansouri Taleghani B, Ahmadpour J, Reiners K, Bigalke H. Naumann M, et al. Among authors: bigalke h. J Neurol Neurosurg Psychiatry. 1998 Dec;65(6):924-7. doi: 10.1136/jnnp.65.6.924. J Neurol Neurosurg Psychiatry. 1998. PMID: 9854974 Free PMC article.

7

Botulinum toxin antibody type A titres after cessation of botulinum toxin therapy.

Dressler D, Bigalke H. Dressler D, et al. Among authors: bigalke h. Mov Disord. 2002 Jan;17(1):170-3. doi: 10.1002/mds.1238. Mov Disord. 2002. PMID: 11835457

8

Botulinum toxin type B in antibody-induced botulinum toxin type A therapy failure.

Dressler D, Bigalke H, Benecke R. Dressler D, et al. Among authors: bigalke h. J Neurol. 2003 Aug;250(8):967-9. doi: 10.1007/s00415-003-1129-6. J Neurol. 2003. PMID: 12928917 Corrected and republished.

9

Botulinum toxin A: dose and immune response.

Bigalke H, Frevert J. Bigalke H, et al. Int J Rehabil Res. 2012 Jun;35(2):93. doi: 10.1097/MRR.0b013e3283531fb1. Int J Rehabil Res. 2012. PMID: 22561214 No abstract available.

10

Ninhydrin sweat test: a simple method for detecting antibodies neutralizing botulinum toxin type A.

Voller B, Moraru E, Auff E, Benesch M, Poewe W, Wissel J, Müller J, Entner T, Bigalke H, Schnider P. Voller B, et al. Among authors: bigalke h. Mov Disord. 2004 Aug;19(8):943-7. doi: 10.1002/mds.20073. Mov Disord. 2004. PMID: 15300661

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

114 results

Search Page

Filters